Analyst Price Targets — NVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 5, 2026 12:38 pm | — | BMO Capital | $45.00 | $47.19 | TheFly | Novo Nordisk price target lowered to $45 from $57 at BMO Capital |
| January 26, 2026 2:36 pm | Evan Seigerman | BMO Capital | $57.00 | $63.80 | StreetInsider | Novo Nordisk (NVO) PT Raised to $57 at BMO Capital |
| December 10, 2025 11:16 am | — | HSBC | $54.00 | $46.36 | TheFly | Novo Nordisk price target raised to $54 from $47 at HSBC |
| December 3, 2025 11:31 am | Thibault Boutherin | Morgan Stanley | $42.00 | $47.43 | TheFly | Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley |
| November 25, 2025 9:26 am | Evan Seigerman | BMO Capital | $46.00 | $44.97 | StreetInsider | Novo Nordisk (NVO) PT Lowered to $46 at BMO Capital |
| October 14, 2025 11:29 am | Evan Seigerman | BMO Capital | $55.00 | $57.50 | TheFly | Novo Nordisk price target raised to $55 from $50 at BMO Capital |
| October 1, 2025 8:03 pm | — | HSBC | $70.00 | $59.17 | TheFly | Novo Nordisk upgraded to Buy from Hold at HSBC |
| September 29, 2025 8:29 am | — | Morgan Stanley | $47.00 | $55.61 | TheFly | Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley |
| July 31, 2025 8:46 am | — | HSBC | $57.00 | $48.89 | TheFly | Novo Nordisk downgraded to Hold from Buy at HSBC |
| July 23, 2025 8:08 pm | Jailendra Singh | Truist Financial | $48.00 | $70.03 | Benzinga | What's Going On With Hims & Hers Stock Wednesday? |
Latest News for NVO
The latest trading day saw Novo Nordisk (NVO) settling at $40.52, representing a -1% change from its previous close.
Reuters, citing IQVIA data, reported that Eli Lilly recorded 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10.
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.
CVS Health has a far more diversified business than Novo Nordisk. Both approaches have perks and disadvantages.
Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's semaglutide, but at a greater expense to muscles and connective tissues, according to a study published this week ahead of peer review.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for NVO.
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.